Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp for BPDCN post-HCT
NCT04317781Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2020
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
A Phase 2 trial of avacincaptad pegol in Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2020; status: terminated.
02
Drugs
avacincaptad pegol
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT04317781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04317781.